Damora Therapeutics Inc (DMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Operating Expenses | 210,872 | 22,260 | 39,905 | 61,207 | 52,227 |
| Operating Income | -210,872 | -22,260 | -39,905 | -61,207 | -52,227 |
| Other Income | 1,083 | 862 | 1,556 | -417 | 475 |
| Pre-tax Income | -209,789 | -21,398 | -38,349 | -61,624 | -51,752 |
| Income Tax | 50 | 41 | N/A | N/A | N/A |
| Net Income Continuous | -209,839 | -21,439 | -38,349 | -61,624 | -51,752 |
| Net Income | $-209,839 | $-21,439 | $-38,349 | $-61,624 | $-51,752 |
| EPS Basic Total Ops | -3.98 | -18.53 | -36.08 | -60.75 | -51.25 |
| EPS Basic Continuous Ops | -153.95 | -18.53 | -36.08 | -60.63 | -51.22 |
| EPS Diluted Total Ops | -3.98 | -18.53 | -36.08 | -60.75 | -51.25 |
| EPS Diluted Continuous Ops | -153.95 | -18.53 | -36.08 | -60.63 | -51.22 |
| EPS Diluted Before Non-Recurring Items | -3.98 | -17.69 | -36.00 | -60.75 | -51.25 |
| EBITDA(a) | $-210,850 | $-22,169 | $-40,067 | $-60,599 | $-51,135 |